OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentPhase 2

IMP1734

IMP1734 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for metastatic cancer.